Evidence mapPaperPMID 38146741Full record

Trial reportAnnals of medicine2023

The effects of Danzhi Jiangtang capsule on clinical indices and vascular endothelial function in patients with impaired glucose tolerance of Qi-Yin deficiency type.

Zhaohui Fang, Zheng Bi, Jindong Zhao, Sihai Wang, Di Wu, Ruimin Lu, Yixuan Lin

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Annals of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Progress and prospects of metal-based immunotherapy in breast cancer.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhaohui FangDepartment of Endocrinology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China.
Zheng BiAnhui University of Traditional Chinese Medicine, Hefei, China.
Jindong ZhaoDepartment of Endocrinology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China.
Sihai WangDepartment of Endocrinology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China.
Di WuAnhui University of Traditional Chinese Medicine, Hefei, China.
Ruimin LuDepartment of Endocrinology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China.
Yixuan LinDepartment of Endocrinology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China.
Anhui University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo observe the effect of Danzhi Jiangtang capsule (DJC) on the clinical indexes and vascular endothelial function indexes in patients with impaired glucose tolerance (IGT).

methodsA total of 106 patients were enrolled and randomly assigned to the treatment group and control group following a four-week washout period. The patients in the control group received a general lifestyle intervention, while those in the treatment group received DJC (2.0 g 3× a day) in conjunction with the intervention given to the control group patients. The physiological and biochemical levels, vascular endothelial function indices, and traditional Chinese medicine (TCM) syndrome ratings of the patients in the two groups were compared after 12 weeks of therapy.

resultsIn the control group, the diastolic blood pressure (DBP) was significantly improved compared with those before treatment (83.31 ± 6.47 vs. 79.21 ± 6.17,

conclusionsTreatment with DJC could significantly improve the physiological and biochemical indicators, vascular endothelial function, and TCM syndrome points of IGT patients, indicating that DJC could be a potential drug to treat patients with IGT of Qi-Yin deficiency type.

Indexed as

Glucose IntoleranceDrugs, Chinese HerbalHumansQiVascular Endothelial Growth Factor AYin Deficiencydanzhi jiangtangDrugs, Chinese HerbalVascular Endothelial Growth Factor ADanzhi Jiangtang capsuleimpaired glucose toleranceprediabetesQi–Yin deficiency typevascular endothelial function

Identifiers

PMID38146741
PMCPMC10763911
OpenAlexW4390230015

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.